Yes, specific nucleases can serve as biomarkers for cancer diagnosis and prognosis. Elevated levels of certain nucleases, such as DNase I, have been associated with tumor presence and progression. Monitoring these levels can provide insights into the effectiveness of treatment and potential recurrence.
